38. Oxbryta

(Global Blood Therapeutics)

Active ingredient: voxelotor
Disease: sickle cell disease
Peak sales estimate: $2.5 billion
Approved: Nov. 25, 2019
Company: Global Blood Therapeutics

The scoop: Patients and doctors in the sickle cell disease community have had a “passionate dissatisfaction” with the status quo, and with its first-ever FDA nod, Global Blood Therapeutics is hoping to change that. Oxbryta, a once-daily oral tablet, marks an advance for patients with the lifelong, inherited blood condition that eventually affects “virtually every organ” in patients’ bodies, an executive told FiercePharma. Sickle cell disease mostly affects African Americans in the U.S., and the drugmaker aims to bring a “paradigm shift” with its launch. Analysts see commercial opportunity, as well, predicting $2.5 billion in peak sales. The drug will bear a list price of $10,417 per month, or $125,000 per year, the company said. — Eric Sagonowsky

38. Oxbryta

Suggested Articles

With case counts surging and top officials infected, the U.K. is joining the testing for Gilead Sciences' much-hyped antiviral candidate remdesivir.

By redeploying staff, the FDA thinks it can respond to COVID-19-related requests and review protocols within 24 hours of receipt.

The partners leveraged their proximity to the initial outbreak and experience with SARS and MERS to build up a library of neutralizing antibodies.